Short review – Management of Immune Thrombocytopenia in adults

Short review


In recent years clinical management of Immune Thrombocytopenia (ITP) has clearly changed due to the emergence of new therapeutics such as Thrombopoietin Receptor Agonists or Rituximab. These agents have been tested in phase III randomized controlled trials and thereby initiated an impulse for the whole field of ITP. Moreover, in 2009 various publications systematically reviewed current practice, presented efforts of standardization as well as new guidelines for diagnosis and treatment of ITP. This short review is intended to summarize these new developments and to propose an up-dated treatment algorithm.


Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenia ITP Therapy Management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Rodeghiero F, Ruggeri M. Immune thrombocytopenic purpura: terminology and definitions response. Blood, 114(9): 2004, 2009CrossRefGoogle Scholar
  2. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 104(9): 2623–2634, 2004CrossRefPubMedGoogle Scholar
  3. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 115(2): 168–186, 2010CrossRefPubMedGoogle Scholar
  4. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88(1): 3–40, 1996PubMedGoogle Scholar
  5. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet, 352(9131): 878, 1998CrossRefPubMedGoogle Scholar
  6. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood, 113(6): 1231–1240, 2009CrossRefPubMedGoogle Scholar
  7. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Kelton JG, et al. The efficacy of H. pylori eradication therapy in H. pylori-infected and uninfected patients with immune thrombocytopenic purpura: a systematic review. Blood, 112(11): 1170, 2008Google Scholar
  8. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. New Eng J Med, 330(22): 1560–1564, 1994CrossRefPubMedGoogle Scholar
  9. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood, 109(4): 1401–1407, 2007CrossRefPubMedGoogle Scholar
  10. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med, 146(1): 25–W5, 2007PubMedGoogle Scholar
  11. Zaja F, Baccarani M, Mazza P, Vianelli N, Bocchia M, Gugliotta L, et al. A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up. Blood, 112(11): 3, 2008Google Scholar
  12. Kaushansky K. Thrombopoietin – the primary regulator of platelet production. Blood, 86(2): 419–431, 1995PubMedGoogle Scholar
  13. Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood, 87(10): 4068–4071, 1996PubMedGoogle Scholar
  14. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet, 373(9664): 641–648, 2009CrossRefPubMedGoogle Scholar
  15. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 371(9610): 395–403, 2008CrossRefPubMedGoogle Scholar
  16. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Reevaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura – a report on 53 cases. Br J Haematol, 74(2): 223–228, 1990CrossRefPubMedGoogle Scholar
  17. Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood, 99(4): 1482–1485, 2002CrossRefPubMedGoogle Scholar
  18. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood, 85(2): 351–358, 1995PubMedGoogle Scholar
  19. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol, 81(1): 19–25, 2006CrossRefPubMedGoogle Scholar
  20. Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med, 116(9): 590–594, 2004CrossRefPubMedGoogle Scholar
  21. Vancine-Califani SMC, De Paula EV, Ozelo MC, Orsi FLA, Fabri DR, Annichino-Bizzacchi JM. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets, 19(7): 489–495, 2008CrossRefPubMedGoogle Scholar
  22. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 110(10): 3526–3531, 2007CrossRefPubMedGoogle Scholar
  23. Figueroa M, Gehlsen J, Hammond D, Ondreyco S, Piro L, Pomeroy T, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. New Eng J Med, 328(17): 1226–1229, 1993CrossRefPubMedGoogle Scholar
  24. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. New Eng J Med, 344(18): 1402–1403, 2001CrossRefPubMedGoogle Scholar
  25. Willis F, Marsh JCW, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol, 114(4): 891–898, 2001CrossRefPubMedGoogle Scholar
  26. Butler JP, Durrant STS, Frost T. Successful remission of chronic, refractory autoimmune thrombocytopenic purpura following non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant, 31(7): 621–622, 2003CrossRefPubMedGoogle Scholar
  27. Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood, 101(1): 71–77, 2003CrossRefPubMedGoogle Scholar
  28. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood, 113(14): 3154–3160, 2009CrossRefPubMedGoogle Scholar
  29. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc. Science, 320(5874): 373–376, 2008CrossRefPubMedGoogle Scholar
  30. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med, 80(6): 1051–1054, 1986CrossRefPubMedGoogle Scholar
  31. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol, 83(2): 122–125, 2008CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Laboratory for Immunological and Molecular Cancer Research (LIMCR), IIIrd Medical Department with Hematology, Medical Oncology, HemostaseologyRheumatology and Infectious Disease of the Private Medical University Hospital SalzburgSalzburgAustria

Personalised recommendations